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Summary
Background.— Temporary mechanical circulatory support may be indicated in some patients
with cardiac failure refractory to conventional therapy, as a bridge to myocardial recovery or
transplantation.devices;
Cardiogenic shock;
Survival
Aims.— To evaluate outcomes in cardiogenic shock patients managed by the primary use of a
paracorporeal ventricular assist device (p-VAD).
Methods.— We did a retrospective analysis of demographics, clinical characteristics and survival
of patients assisted with a Thoratec® p-VAD.
Abbreviations: BiVAD, biventricular assist device; ECMO, extracorporeal membrane oxygenation; IABC, intra-aortic balloon
counterpulsation; LVAD, left ventricular assist device; p-VAD, paracorporeal ventricular assist device; RVAD, right ventricular assist device.
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MOTS CLÉS
Dispositifs
d’assistance
ventriculaire ;
Choc cardiogénique ;
Survie
Contrairement aux systèmes percutanés, ce système assure une perfusion pulsée avec une
décharge optimale des cavités cardiaques défaillantes et autorise la réhabilitation des patients.
Le recours à une assistance biventriculaire doit être libéral en cas de défaillance d’organes
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ackground
emporary mechanical circulatory assistance may be indi-
ated in some patients with cardiac failure refractory to
onventional therapy, to bridge patients to myocardial
ecovery or heart transplantation. Numerous mechanical
upport devices have been used with success in this set-
ing. The devices differ mainly in their basic pump features
positive displacement versus rotary), the type of blood ﬂow
hey provide (pulsatile versus continuous), their intra-, para-
r extracorporeal positioning, and their potential for uni-
r biventricular support. Although ventricular assist devices
ave repeatedly shown their efﬁcacy in bridging cardio-
enic shock patients [1], several groups advocate the use
f extracorporeal venoarterial membrane oxygenation [2],
p
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xtracorporeal Abiomed BVS 5000 (Abiomed Inc., Danvers,
A, USA [3]) or CentriMag (Levitronix LLC, Waltham, MA,
SA [4]) pumps, or latest generation percutaneous rotary
umps [5] for initial support in a two-step bridge-to-decision
trategy.
Since 1996, we have used a support strategy for
atients with cardiogenic shock, which aims to achieve
apid restoration of pulsatile perfusion, optimal cardiac
hamber unloading, liberal indication of biventricular sup-
ort, preferential paracorporeal positioning and the use of
ong-term ventricular assist devices as ﬁrst-line therapy,M. Kirsch et al.
Results.— p-VADs were used in 84 patients with cardiogenic shock secondary to acute myocar-
dial infarction (35%), idiopathic (31%) or ischaemic (12%) cardiomyopathy, myocarditis or other
causes (23%). Before implantation, 23% had cardiac arrest, 38% were on a ventilator and 31%
were on an intra-aortic balloon pump. Cardiac index was 1.6± 0.5 L/min/m2 and total bilirubin
levels were 39± 59mol/L. During support, 29 patients (35%) died in the intensive care unit
and seven (10%) died after leaving. Forty-seven patients (56%) were weaned or transplanted,
with one still under support. Despite signiﬁcantly more advanced preoperative end-organ dys-
function, survival rates were similar in patients with biventricular devices (74%) and those
undergoing isolated left ventricular support (24%) (63% versus 45%, respectively; p = 0.2). Actu-
arial survival estimates after transplantation were 78.7± 6.3%, 73.4± 6.9% and 62.6± 8.3% at
1, 3 and 5 years, respectively.
Conclusions.— Our experience validates the use of p-VAD as a primary device to support patients
with cardiogenic shock. In contrast to short-term devices, p-VADs provide immediate ventricular
unloading and pulsatile perfusion in a single procedure. Biventricular support should be used
liberally in patients with end-organ dysfunction.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— L’assistance mécanique de la circulation peut être indiquée chez certains patients
en choc cardiogénique en attente de recupération ou de transplantation. Nous rapportons notre
expérience avec le système pneumatique paracorporel Thoratec® pour assister les patients en
état de choc cardiogénique primaire.
Résultats.— Quatre-vingt quatre patients ont été assistés pour un état de choc lié à : un infarc-
tus du myocarde (35 %), une cardiomyopathie dilatée idiopathique (31 %) ou ischémique (12 %),
ou d’autres causes. Avant l’assistance, 23 % des patients ont subit un arrêt cardiaque, 38 %
étaient sous ventilation artiﬁcielle et 31 % étaient assistés par un ballon de contre-pulsion
intra-aortique. L’index cardiaque a été de 1,6± 0,5 L/min/m2 et la bilirubinémie totale de
39± 59mol/L. Après l’assistance, 29 patients (35 %) sont décédés pendant leur séjour initial
en réanimation et sept (10 %) sont décédés après leur sortie de réanimation. Quarante-sept
patients (56 %) ont été sevrés ou transplantés. Malgré une altération signiﬁcativement plus
importante de la fonction rénale et hépatique préopératoire, la survie des patients sous assis-
tance biventriculaire (74 %) a été similaire à celle des patients sous assistance ventriculaire
gauche isolée (respectivement, 39/62 [63 %] vs 9/20 [45 %], p = 0,2). La probabilité de survie
après transplantation a été de 78,7 %± 6,3, 73,4 %± 6,9 et 62,6 %± 8,3 à un, trois et cinq ans,
respectivement.
Conclusions.— L’assistance circulatoire par le système pneumatique paracorporel Thoratec®
donne des taux de survie acceptables chez les patients en état de choc cardiogénique primaire.roviding a direct bridge to transplantation or recovery.
o achieve these goals, we have chosen the versatile
horatec® paracorporeal ventricular assist device (p-VAD;
horatec Laboratories Corporation, Pleasanton, CA, USA).
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The present study reviews our overall experience in 84 con-
secutive patients with cardiogenic shock who were assisted
primarily with this device as a bridge to transplantation or
recovery.
Patients and methods
Patients
Between 01 January 1996 and 30 June 2008, 84 consecu-
tive patients with primary cardiogenic shock were assisted
using the Thoratec® p-VAD in our department. Patients with
postcardiotomy shock, early cardiac allograft failure or right
ventricular dysfunction after implantation of another type
of left ventricular assist device were not included.
Device
The Thoratec® p-VAD (Fig. 1) is a mechanical circulatory sup-
port device with three components: a blood pump, which
has an effective stroke volume of 65mL and can deliver
pulsatile ﬂows of 1.3 to 7.1 L/min; inﬂow and outﬂow can-
nulae, which connect the prosthetic ventricle to the heart;
and a drive console that powers the pump pneumatically.
The blood pump is in a paracorporeal position on the ante-
rior abdominal wall. The device can be used to support
the left ventricle (left ventricular assist device [LVAD]), the
right ventricle (right ventricular assist device [RVAD]) or
both ventricles (biventricular assist device [BiVAD]). Left
heart support is achieved by cannulating the left atrium or
the apex of the left ventricle (inﬂow) and the ascending
aorta (outﬂow). Right heart support is achieved by cannu-
lating the right atrium or the right ventricle (inﬂow) and
the pulmonary artery (outﬂow). Indications for biventricu-
lar support were at the discretion of the operating surgeon
but included overt right ventricular dysfunction at operation
Figure 1. Schematic drawing of univentricular or biventricular
support using the Thoratec® paracorporeal ventricular assist device.
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s assessed by visual inspection or echocardiography and/or
ssociated end-organ dysfunction as indicated by elevated
iver enzymes and renal failure.
nticoagulation protocol
fter surgery, anticoagulation was started within 8 to 12 h
sing intravenous heparin to achieve an anti-Xa activity
etween 0.3 and 0.4 IU/L.
Aspirin was started 24 h after surgery in the absence
f bleeding or thrombocytopaenia at a daily dose of
50mg. Aspirin doses were subsequently adjusted to
n vitro platelet function tests, as reported previously
6].
Oral antivitamin K therapy was started after removal of
ll chest drains and extubation to maintain an international
ormalized ratio between 3 and 4. Since 2004, however,
ntivitamin K therapy was not used and was replaced (renal
unction permitting) by subcutaneous low-molecular-weight
eparin (enoxaparin) to achieve an anti-Xa activity between
.5 and 0.6 IU/L.
ata collection
ince 2004, patient data have been collected prospectively
n the Henri Mondor Mechanical Circulatory Support Devices
egistry. For patients implanted before this date, hospital
ecords were reviewed and entered into the registry ret-
ospectively. The present study was approved by our local
edical Ethics Committee, and the deﬁnitions used were
hose provided previously by the International Society for
eart and Lung Transplantation Mechanical Circulatory Sup-
ort Device Database [7].
tatistical analysis
tatistical analysis was performed using SPSS Base 12.0
tatistical software (SPSS Inc., Chicago, IL, USA). Categori-
al variables were expressed as percentages and compared
sing the Chi-square or Fisher’s exact test, as appropriate.
ontinuous variables were expressed as the mean± 1 stan-
ard deviation and were compared using the Mann-Whitney
est for unpaired groups to avoid the assumption of normal-
ty. Variables expressing time were reported using medians
ith 5th and 95th percentiles. Survival data were analysed
ith standard Kaplan-Meier actuarial techniques for esti-
ation of survival probabilities. For survival estimates of
atients under support, patients were censored at the time
f device explantation because of weaning or transplan-
ation. A two-tailed p-value less than 0.05 was taken to
ndicate statistical signiﬁcance.
esults
atient characteristicshe series comprised 73 men and 11 women, aged
2.9± 12.3 years (range: 13.9 to 63.3 years). Causes of heart
ailure are listed in Table 1. Three (4%) patients had a his-
ory of previous coronary artery bypass graft surgery, which
512
Table 1 Primary causes of heart failure.
Number of patients (%)
Ischaemic heart disease
Acute myocardial
infarction
29 (35)
Dilated ischaemic
cardiomyopathy
10 (12)
Primary cardiomyopathies
Genetic
arrhythmogenic right
ventricular dysplasia
1 (1)
Mixed
idiopathic 26 (31)
familial 4 (5)
toxic 4 (5)
Acquired
myocarditis 5 (6)
giant-cell myocarditis 1 (1)
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Total 84 (100)
as associated with a left ventricular restoration procedure
n one patient.
tatus at admission
ineteen (23%) patients had experienced cardiac arrest
ithin 24 h of implantation. The type and level of haemo-
ynamic monitoring at admission varied widely between
atients depending on the severity of the cardiac decompen-
ation and local logistic issues. Thus, preoperative cardiac
ndex values (n = 44) were gathered from echocardiographic
r pulmonary artery catheter estimations and are reported
n Table 2. Mean values of preoperative laboratory tests
re also provided in Table 2. Thirty-two (38%) patients
ad abnormal creatinine values greater than or equal to
50mol/L and 41 (49%) had aspartate transaminase values
hree times normal or greater.
reimplantation support
hirty-two (38%) patients needed preoperative mechanical
entilation initiated at a median of 1.0 day (5th and 95th
ercentiles, 0.0 and 20.6 days) before p-VAD implantation.
Preoperative intravenous haemodynamic drug support
as used in 79 (94%) patients. Among the ﬁve patients
ho had no preoperative haemodynamic drug support, two
ere under intra-aortic balloon counterpulsation (IABC)
nd two had underlying cardiac diseases that made them
ntolerant of inotropes (restrictive or hypertrophic car-
iomyopathy). The last patient had been weaned recently
rom inotropic support initiated after acute myocardial
nfarction complicated by mitral valve insufﬁciency. He was
cheduled for a coronary artery bypass graft and valve
epair, but was switched intraoperatively to a bridge to
ransplantation strategy owing to the macroscopic extent
f infarction. Thirty-one (37%) patients were treated with
single drug, 42 (50%) with a combination of two drugs,
P
M
p
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nd six (7%) received a combination of three drugs. Intra-
enous drugs included dobutamine (N = 70 [83%]; mean
ose: 12.6± 5.4g/kg/min), adrenaline (N = 39 [46%]; mean
ose: 4.2± 4.5mg/h), dopamine (N = 16 [19%]; mean dose
.6± 4.2g/kg/min), phosphodiesterase inhibitors (N = 5
6%]) and norepinephrine (N = 3 [4%]). When used, dopamine
as administered at infusion rates of at least 5g/kg/min
n most cases (14/16 patients).
Twenty-six (31%) patients had preoperative IABC, which
as initiated a median of 1.0 day (5th and 95th percentiles,
.0 and 28.8 days) before p-VAD implantation. However, no
atient had previous haemodynamic support with another
echanical circulatory support system such as a centrifugal
ump or extracorporeal membrane oxygenation (ECMO). In
ddition, no patient had haemoﬁltration or dialysis before
-VAD implantation.
urgical technique
ixty-two (74%) patients received biventricular support, 20
24%) patients received isolated left ventricular support
nd two (2%) patients received isolated right ventricu-
ar support. LVAD patients were assisted mainly for acute
yocardial infarction (85%) and had a higher rate of preoper-
tive IABC (Table 2). BiVAD patients had signiﬁcantly higher
reoperative central venous pressures and total bilirubin
evels (Table 2).
BiVADs and LVADs (N = 82 [98%]) were implanted using
ardiopulmonary bypass, while isolated RVAD implantation
as achieved without cardiopulmonary bypass (N = 2 [2%]).
ean cardiopulmonary bypass duration was 152.8± 60.0min
extremes: 58 and 362min). Aortic cross clamp was used
ccording to the operating surgeon’s preference in 53
atients (63%) and averaged 64.3± 29.5min (range: 24 to
75min). In the latter patients, myocardial protection was
chieved using cold crystalloid cardioplegia. Concomitant
oronary artery bypass graft was performed in ﬁve (6%)
atients.
LVADs were implanted between the left ventricular apex
nd the ascending aorta in all instances. RVAD (N = 64) inﬂow
annulae were placed either in the right atrium (N = 36
56%]) or the right ventricle (N = 28 [44%]) to optimize ven-
ricular unloading.
verall survival after p-VAD implantation
he total duration of follow-up after device implanta-
ion was 2456.2 patient-months and the median duration of
ollow-up was 6.3 months (5th and 95th percentiles, 0.11
nd 115.4 months). Actuarial survival estimates after device
mplantation (patients not censored at the time of device
xplantation because of weaning or transplantation) were
9.1± 5.0%, 48.7± 5.5%, 41.9± 5.5% and 38.4± 5.6% at 1
onth, 1 year, 3 years and 5 years, respectively (Fig. 2).
utcomes under support
urvival
atients were assisted for a total of 5894 patient-days.
edian duration of support was 42.0 days (5th and 95th
ercentiles, 2.3 and 268.0 days). Forty-seven patients (56%)
ere successfully bridged to transplantation (N = 42 [50%])
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Table 2 Preimplantation demographic, haemodynamic and laboratory variables.
Variables All patients
(N = 84)
Biventricular assist
device (N = 62)
Left ventricular
assist device (N = 20)
pa
Age (years) 42.9± 12.3 41.5± 12.8 48.3± 8.7 0.05
Sex (men/women) 73/11 53/9 19/1 0.45
Body surface area (m2) 1.85± 0.23 1.83± 0.23 1.89± 0.24 0.62
Acute myocardial infarction (N [%]) 29 (35) 12 (19) 17 (85) 0.0001
Preoperative mechanical ventilation (N [%]) 32 (38) 24 (39) 8 (40) 1.0
Duration of mechanical ventilation (days) 2.2± 1.3 6.4± 1.4 0.5± 0.2 0.46
Haemodynamics
Cardiac arrest < 24 h (N [%]) 19 (23) 14 (23) 4 (20) 1.0
Cardiac index (L/min/m2) 1.6± 0.5 1.6± 0.5 1.7± 0.4 0.8
Central venous pressure (mmHg) 19± 9 20± 8 9± 5 0.001
Intra-aortic balloon pump (N [%]) 26 (31) 11 (18) 15 (75) 0.0001
Laboratory
Sodium (mEq/L) 131± 9 130± 10 135± 7 0.07
Creatinine (mol/L) 160± 78 164± 78 149± 80 0.15
Blood urea nitrogen (mmol/L) 13.2± 8.7 14.3± 9.8 9.8± 3.3 0.08
White blood cells (109/L) 13.4± 5.8 12.5± 6.1 16.1± 4.0 0.002
Platelets (109/L) 221± 97 213± 95 246± 106 0.2
Haematocrit (%) 35.9± 8.0 34.7± 7.5 38.9± 9.1 0.1
Total bilirubin (mol/L) 38.5± 59.3 46.2± 66.8 15.5± 7.8 0.000
Aspartate aminotransferase (U/L) 502± 1019 586± 1143 261± 362 0.7
Alanine aminotransferase (U/L) 415± 878 493± 987 184± 256 0.61
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or recovery (N = 5 [6%]). One patient (1%) was still awaiting
transplantation under LVAD support at the time of follow-up.
Table 3 shows survival rates to weaning, transplantation and
hospital discharge according to the type of support (BiVAD,
LVAD or RVAD). Overall actuarial estimates of survival under
mechanical circulatory support (patients censored at the
time of device explantation because of weaning or trans-
plantation) were 69.7± 5.2%, 59.2± 6.0% and 52.4± 6.4% at
1, 2 and 3 months after implantation, respectively (Fig. 3A).
Survival to transplantation or recovery was not signif-
icantly different in LVAD and BiVAD patients (9/20 [45%]
versus 39/62 [63%], respectively; p = 0.2). Similarly, there
was no signiﬁcant difference in actuarial survival between
LVAD and BiVAD patients (Fig. 3B) (p = 0.18).Morbidity and mortality
The adverse events observed most frequently during
mechanical circulatory support are listed in Table 4. The
t
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Table 3 Overall outcome rates after ventricular assist device
Type of support Number of patients Nu
Die
sup
Biventricular assist device 62 23
Left ventricular assist device 20 11
Right ventricular assist device 2 2 (
Total 84 36group.
ncidences of adverse events were not signiﬁcantly different
n LVAD and BiVAD patients (Table 4). However, right ven-
ricular dysfunction was noted in four LVAD patients (20%).
urthermore, mean duration of postoperative inotrope sup-
ort was signiﬁcantly longer for LVAD patients than for BiVAD
atients (8.5± 6.7 days versus 1.1± 2.1 days, respectively;
= 0.002). On the other hand, ﬁve (8%) BiVAD patients expe-
ienced right-sided thromboembolic complications, which
ere associated with pulmonary perfusion defects on
entilation—perfusion scan in four patients. In one of these
atients, the extent of perfusion defects precluded iso-
ated heart transplantation because of suspected increase of
ulmonary vascular resistances, and the patient died after
80 days of support while waiting for combined heart—lung
ransplantation.
Thirty-six (43%) patients died during mechanical circu-
atory support after a median of 9.0 days of support (5th
nd 95th percentiles, 1.9 to 277.7 days). Among these, 29
35%) patients did not recover sufﬁciently to allow intensive
implantation.
mber of patients (%)
d on
port
Weaned Transplanted Ongoing Survived to
discharge
(37) 3 (5) 36 (58) 0 (0) 31 (50)
(55) 2 (10) 6 (30) 1 (5) 7 (37)
100) 0 (100) 0 (0) 0 (0) 0 (0)
(43) 5 (6) 42 (50) 1 (1) 38 (47)
514 M. Kirsch et al.
Table 4 Adverse events observed during mechanical circulatory support.
Events Number of patients (%)
All patients Biventricular assist
device (N = 62)
Left ventricular
assist device (N = 20)
Surgical reexploration
Bleeding 19 (22) 16 (26) 2 (10)
Cardiac tamponade 12 (14) 9 (15) 3 (15)
Infection 56 (67) 44 (71) 12 (60)
Bronchopulmonary 28 (33) 21 (34) 7 (35)
Blood cultures > 0 21 (25) 17 (27) 4 (20)
Ventricular assist device cannulae 18 (21) 16 (26) 2 (10)
Urinary 15 (18) 12 (19) 3 (15)
Mediastinal 4 (5) 4 (7) 0 (0)
Renal dysfunction 27 (32) 20 (32) 6 (30)
Neurological 25 (30) 18 (29) 7 (35)
Cerebral embolism 18 (21) 13 (21) 5 (25)
Intracranial bleeding 5 (6) 5 (8) 0 (0)
Other causes 2 (2) 0 (0) 2 (10)
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Hepatic dysfunction 14 (17)
Drive console (TLCII) arrest 1 (1)
are unit dismissal and died after a median of 8.0 days of
upport (5th and 95th percentiles, 1.5 to 71.5 days). The
ther seven patients died after intensive care unit dismissal
t a median of 72.0 days of support (5th and 95th per-
entiles, 30.0 to 480.0 days). Causes of death in both groups
re listed in Table 5. During initial intensive care unit stay,
eaths were mostly related to multiple organ dysfunction
yndrome. After intensive care unit dismissal, deaths were
ostly related to infection and bleeding complications.
utcomes after mechanical circulatory
upport
ecovery group
ive patients were explanted because of myocardial recov-
ry after a median of 37.0 days of support (5th and 95th
F
p
a
m
Table 5 Causes of death during mechanical circulatory suppo
Cause of death Number of
In intensive
Multiple organ dysfunction syndrome 15
Neurological
Ischaemic 3
Bleeding 1
Infection 3
Mesenteric ischaemia 3
Right ventricular failure 1
Pulmonary
Acute respiratory distress syndrome 3
Emboli —
Cancer (lung) —
Device failure —
Total (N = 36) 2914 (23) 4 (22)
9 (15) 3 (15)
0 (0) 1 (5)
ercentiles, 13.0 to 94.0 days). Among these, one patient
ho had been assisted for 63 days for acute myocardial
nfarction died of ventricular ﬁbrillation shortly after device
xplantation. Another patient, who had been assisted for 94
ays for fulminant myocarditis, deteriorated rapidly after
evice retrieval and underwent successful emergent trans-
lantation within 24 h. The three remaining patients, who
ad been assisted for myocarditis, acute myocardial infarc-
ion and sudden cardiac arrest, were explanted successfully
nd became long-term survivors.
ransplantation group
orty-two patients were successfully bridged to trans-
lantation after a median of 57.0 days of support (5th
nd 95th percentiles, 5.2 to 343.4 days). Thirty-day-
ortality after transplantation for these 42 patients, plus
rt.
deaths
care unit After intensive care unit dismissal
—
—
2
2
—
—
—
1
1
1
7
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Figure 2. Overall actuarial estimates of survival after ventric-
ular assist device implantation (N = 84). Error bars represent± 1
standard error of the mean.
Figure 3. Actuarial estimates of survival under mechanical cir-
culatory support in (A) the whole patient population (N = 84) and
in (B) patients under biventricular (N = 62) and left ventricular sup-
port (N = 20). Patients were censored at time of transplantation or
weaning of device. Error bars represent± 1 standard error of the
mean.
F
t
t
t
t
L
2
7
r
i
L
D
I
r
a
T
ﬁ
t
r
t
i
a
t
a
t
s
i
t
p
r
s
p
n
p
p
p
c
a
tigure 4. Actuarial estimates of survival after orthotopic heart
ransplantation (N = 43). Error bars represent± 1 standard error of
he mean.
he patient mentioned previously who required emergent
ransplantation after device explantation, was 16% (7/43).
ong-term follow-up of the 43 transplanted patients reached
171.7 patient-months. Actuarial survival estimates were
8.7± 6.3%, 73.4± 6.9% and 62.6± 8.3% at 1, 3 and 5 years,
espectively (Fig. 4). There was no signiﬁcant difference
n posttransplantation survival between BiVAD (N = 37) and
VAD (N = 6) patients (p = 0.83, results not shown).
iscussion
n the present study we have analysed our overall expe-
ience with patients experiencing primary cardiac failure
nd undergoing mechanical circulatory support using the
horatec® p-VAD as a ﬁrst-line assist device. Our results con-
rm that this strategy offers acceptable survival rates to
ransplantation or recovery.
Outcome in our patient population was similar to that
eported by other groups using the same device [8,9] and
o that in published registry data [1]. However, mortal-
ty under support still remains soberingly high and is an
rea in which major improvements can be made. Most of
he deaths in our series occurred soon after implantation
nd before intensive care unit dismissal, and were related
o multiple organ dysfunction syndrome. Adequate patient
election and timing of implantation are among the most
mportant factors inﬂuencing success of mechanical circula-
ory support, but are also the most difﬁcult aspects of the
rocedure. Several studies have identiﬁed preimplantation
isk factors for adverse outcome under support [10,11], and
creening scales to help the decision process have been pro-
osed [12]. In a previous analysis, we have shown that the
eed for preoperative adrenaline therapy was the sole inde-
endent risk factor for death in the intensive care unit in
atients assisted with the Thoratec® p-VAD [13]. To improve
atient selection, some groups advocate a staged approach,
onsisting of initial support with short-term devices such
s venoarterial extracorporeal membrane oxygenation [2],
he extracorporeal Abiomed BVS 5000 (Abiomed Inc., Dan-
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ers, MA, USA [3]) or CentriMag (Levitronix LLC, Waltham,
A, USA [4]) systems, or the latest-generation percutaneous
otary pumps [5]. Patients who recover may subsequently be
witched to long-term devices. The rationale underlying this
ridge-to-decision strategy is to use less invasive devices to
educe the initial surgical aggression in critically ill patients
nd/or to avoid implantation of a costly long-term device
n patients who are unlikely to survive or who might present
ontraindications to heart transplantation. This strategy has
een shown to be effective in selected cardiogenic shock
atients and might optimize resource utilization. However,
he cost-effectiveness of the two-stage approach has not yet
een demonstrated. Most importantly, however, we feel that
he various reported two-stage approaches do not maximize
he chances of end-organ recovery. Indeed, the aggression of
he second operation required to implant a long-term device
ight interfere with patient recovery. Furthermore, none
f the currently available short-term assist devices com-
ines pulsatile perfusion, optimal cardiac unloading and the
ossibility for biventricular support.
The importance of pulsatile perfusion remains controver-
ial and only a few studies have evaluated it in the speciﬁc
etting of cardiogenic shock. Recently, De Backer et al. [14]
nderscored the importance of microvascular blood ﬂow
lterations in patients with acute heart failure or cardio-
enic shock by showing that the extent of these alterations
as related to patient survival. In an experimental study,
aba et al. [15] showed that nonpulsatile perfusion altered
icrovascular perfusion signiﬁcantly. Thus, opting for non-
ulsatile perfusion in cardiogenic shock patients might
urther aggravate microvascular perfusion defects, resulting
n inadequate tissue oxygenation and subsequent multiple
rgan dysfunction syndrome. Indeed, several experimental
tudies performed in models of postmyocardial infarction
ardiogenic shock have reported more complete and rapid
ecovery of renal, hepatic and metabolic function with
ulsatile perfusion compared with nonpulsatile perfusion
16,17].
Adequate cardiac chamber unloading is a prerequi-
ite not only for adequate myocardial recovery but also
or optimal organ recovery. ECMO provides only incom-
lete left ventricular unloading, potentially leading to
ulmonary hypertension, edema and haemorrhage. Thus,
CMO patients may require simultaneous decompression of
he left ventricle through continued inotropic drug support,
trial septostomy or a transatrial catheter. Similarly, support
evices designed to drain the left atrium (TandemHeart,
biomed BVS 5000, CentriMag) will not capture all the blood
eturning from the lung. In cases of profound ventricular
ysfunction without any ejection, there will be signiﬁcant
tasis in the left ventricular chamber, impeding myocardial
ecovery and exposing the patient to upstream pulmonary
nd right ventricular dysfunction. In contrast, direct ven-
ricular cannulation usually allows satisfactory ventricular
nloading, thereby providing optimal conditions not only for
yocardial recovery but also for organs located upstream.
n addition, the Thoratec® p-VAD has a distinct advantage
n that its dual drive console allows application of negative
ressures (vacuum) to the pump sac to optimize pump sac
lling and ventricular unloading.
Preoperative prediction of the need for biventricular
upport remains difﬁcult. Although some haemodynamic
m
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redictors of right ventricular dysfunction after LAVD
mplantation have been proposed, they are unreliable [18].
ther groups have stressed the importance of the patient’s
eneral clinical condition, while variables such as emer-
ent implantation, preoperative mechanical ventilation and
igher preoperative bilirubin and creatinine levels have
een associated with biventricular failure [19,20]. Moreover,
he recently published ‘‘right ventricular failure score’’
tratiﬁes the risk of right ventricular failure effectively using
nly clinical variables, such as preoperative vasopressor
upport, and increased preoperative aspartate aminotrans-
erase (≥ 80UI/L), bilirubin (≥ 2.0m/dL) and creatinine
≥ 2.3mg/dL) concentrations [21].
One limitation of the present study is the absence of def-
nite criteria for determining which patients should receive
iVAD versus LAVD: the decision was left at the discretion of
he operating surgeon and relied mainly on intraoperative
isual inspection of right ventricular contractility and preop-
rative end-organ dysfunction. Interestingly, BiVAD patients
ended to have improved outcomes compared with LAVD
atients despite more advanced preoperative end-organ
ysfunction indicated by higher preoperative blood urea
itrogen and total bilirubin values. Both these biological
ariables have been shown to be independent risk factors for
eath in patients assisted with the Thoratec® p-VAD [10,11].
his ﬁnding contrasts with the worldwide experience [1]
nd that of other groups who describe better outcomes
fter LVAD support than after BiVAD support [19]. This dis-
repancy might be related to the small size of our LVAD
atient population. Alternatively, our LVAD patients were
lder and experienced acute myocardial infarction more
requently than BiVAD patients. Both variables have been
ssociated with poorer outcome under mechanical circula-
ory support [10,22]. Importantly, however, LAVD patients
re inherently exposed to right ventricular dysfunction,
hich occurred in 20% of our LVAD patients. Thus, our
VAD patients required signiﬁcantly longer postimplantation
notropic support than our BiVAD patients. The need for
ubsequent right ventricular assist device implantation or
he need for prolonged inotropic support has been associ-
ted with adverse outcome in patients under LVAD support
23]. In contrast, biventricular support prevents the risk of
ight ventricular dysfunction and allows rapid weaning of
notropic drugs. However, with twice as many cannulae and
umps, the risks of bleeding, infection and thromboembolic
vents is expected to be higher in BiVAD patients than in
VAD patients. Thus, the proportion of patients who required
eexploration for bleeding or who developed device can-
ulae infection tended to be higher in BiVAD than in LVAD
atients. Furthermore, although the proportion of patients
ith left-sided thromboembolic complications was similar
n both groups, some BiVAD patients developed repeated
ight-sided asymptomatic thromboembolic complications
etected by systematic pulmonary ventilation—perfusion
cans. We hypothesize that the greater length of the outﬂow
raft and the lower pneumatic driving pressures resulting
n lower blood velocities in RVADs facilitate thrombus for-
ation. Although asymptomatic, the repetition of these
inor events during prolonged support might progressively
ncrease pulmonary vascular resistances and contribute to
ight ventricular dysfunction after transplantation. How-
ver, our experience suggests that these drawbacks do
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not outweigh the haemodynamic advantages provided by
biventricular support in the perioperative period. Thus, like
other groups [24,25], we advocate liberal use of BiVAD
support in patients with cardiogenic shock and end-organ
dysfunction.
Although the paracorporeal position of the p-VAD exposes
patients to a signiﬁcant risk of cannulae infection (20%)
and hampers home discharge, it provides several distinctive
advantages in the critically ill patient. Indeed, in contrast
to extracorporeal devices, it allows early patient mobi-
lization and rehabilitation. Unlike implantable devices, it
can be used in a wide range of patient body sizes. Fur-
thermore, it avoids the extensive tissue dissection required
for the placement of implantable ventricular assist devices
and thus reduces the risk of pump-pocket haematoma
and/or infection. Indeed, pump-pocket infections are asso-
ciated with particularly poor outcomes, with mortality
reaching 30% in some series [9]. Although the attractive
biodesign of the recently developed Thoratec® implantable
ventricular assist device may improve its implantabil-
ity, we are still reluctant to use it in the critically ill
patient.
Conclusions
Our experience validates the use of the p-VAD as a pri-
mary device to support patients with cardiogenic shock. In
contrast to short-term assist devices, p-VADs provide imme-
diate ventricular unloading and adequate organ perfusion in
a single procedure, and allow prolonged support with effec-
tive rehabilitation. Biventricular support should be used
liberally in patients with end-organ dysfunction. The cost-
effectiveness of this approach could probably be improved
by using low-cost prosthetic ventricles for initial support
with the possibility of their subsequent replacement by more
durable ones, at bedside and without reoperation, in cases
of prolonged support.
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